Related Experiment Video
Updated: Mar 3, 2026
Promotion of Survival and Differentiation of Neural Stem Cells with Fibrin and Growth Factor Cocktails after Severe Spinal Cord Injury
Published on: July 27, 2014
Increased fibroblast growth factor 21 is associated with metabolic syndrome in chronic spinal cord injury: A
Sintip Pattanakuhar1,2,3,4, Nattayaporn Apaijai2,3,5, Nipon Chattipakorn2,3,5
1Department of Rehabilitation Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Objective:
To investigate the association between plasma fibroblast growth factor 21 (FGF21) and conventional metabolic parameters in people with chronic spinal cord injury (SCI).
Design:
A cross-sectional study.
Setting:
An SCI-specialized rehabilitation facility in a university hospital.
Participants:
Fifty-six participants with chronic SCI (duration of SCI ≥ 1 year).
Intervention:
Not applicable.
Main Outcome Measure:
After informed consent, demographic and SCI-related parameters were collected. Metabolic parameters, including anthropometric measures, body composition assessed by dual-energy x-ray absorptiometry, and blood tests, were evaluated. Plasma FGF21 levels were determined using an enzyme-linked immunosorbent assay (ELISA) method. Metabolic syndrome was diagnosed by the American Heart Association (AHA)/the National Cholesterol Education Program (NCEP) III Criteria. Associations between plasma FGF21 levels and other parameters were determined using multivariable linear regression analyses.
Results:
Among 56 participants, 37 people (66%) were male. The mean (SD) age was 43.8 (10.6) years. Twelve people (21%) had tetraplegia and 14 people (15%) had complete SCI. Twelve (21%) participants were diagnosed with obesity, prediabetes, and metabolic syndrome (MetS). Using multivariable analysis adjusting for all demographic data, medical conditions, and metabolic parameters, being diagnosed with MetS had an independent positive association with plasma FGF21 level (P = 0.020, Beta coefficient = 0.776 [95%CI: 0.126-1.426]; multivariable linear regression analysis).
Conclusions:
In people with chronic SCI, MetS is an independent positive associated factor of plasma FGF21 level, which may suggest the presence of FGF21-resistant condition. This result addresses the interesting role of FGF21 in the development of cardiometabolic diseases in people with chronic SCI.
